Document is current
Any future updates will be listed below
-
Authors
Hirohama, Daigoro https://orcid.org/0000-0002-1885-1263
Fadista, João
Ha, Eunji https://orcid.org/0000-0001-8618-8347
Liu, Hongbo
Abedini, Amin https://orcid.org/0000-0002-8875-0070
Levinsohn, Jonathan
Vassalotti, Allison
Zeng, Li
Li, Chenyu
Mohandes, Samer
Vitale, Steven
Shungin, Dmitry
Nguyen, Thao
Niewczas, Monika A. https://orcid.org/0000-0003-2371-595X
Olsson, Niclas https://orcid.org/0000-0002-9746-0542
McAllister, Fiona E. https://orcid.org/0000-0002-7862-6711
Karihaloo, Anil
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
-
Funding
Funding for this research was provided by:
National Institutes of Health
Research grant from Manpei Suzuki Diabetes Foundation
National Institutes of Health
- License Information
-
More Information
Article History
Received: 14 July 2024
Accepted: 1 July 2025
First Online: 12 August 2025
Competing interests
: The laboratory of K.S. (including D.H., E.H., H.L., A.A., J.L., A.V., L.Z., C.L., S.M. and S.V.) is supported by Gilead, Novo Nordisk, Novartis, GlaxoSmithKline, BIPI, Regeneron, Genentech and Calico Life Sciences. K.S. is on the scientific advisory board of Pfizer. T.N., N.O. and F.E.M. are employees of Calico Life Sciences. J.F., D.S. and A.K. are employees of Novo Nordisk. All other authors declare no competing interests.
